Previous 10 | Next 10 |
home / stock / mrna / mrna articles
Financial Times Europe Set To Launch Anti-Subsidy Probe Into Chinese Electric Vehicles Chinese electric vehicle company stocks, including XPe...
Moderna Inc (NASDAQ: MRNA) announced its intentions to launch up to 15 new products and advance up to 50 mRNA medicines into clinical trials o...
The Centers for Disease Control and Prevention (CDC) has officially endorsed COVID-19 booster shots for individuals six months and older ...
The U.S. Food and Drug Administration on Monday approved and authorized updated COVID-19 vaccines by Moderna Inc (NASDAQ: MRNA) and partners P...
Advancements in healthcare and medicine have helped contribute to the reduction in child mortality rates, plummeting from 185 per 1,000 births a ce...
On Tuesday, UK regulators joined their US and European peers in approving an updated COVID-19 vaccine by Pfizer Inc (NYSE: PFE) and ...
Wall Street Journal iPhone 15 May Face Hurdle In China As Government Officials Receive Foreign Device Ban The Chinese government has banned its of...
Moderna Inc's (NASDAQ: MRNA) clinical trial data from its research assay confirm that its updated COVID-19 vaccine generates an 8.7-fold i...
Moderna Inc (NASDAQ: MRNA) shares are trading lower by 2.4% to $113.80 Thursday afternoon. The stock has seen volatility in recent sessions amid&nb...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...